Factors Informing Adjuvant Treatment Selection in HER2+ Early Breast Cancer

A look at how patient response to neoadjuvant treatment for HER2+ early breast cancer informs adjuvant treatment selection.

Related Videos
Expert on urothelial carcinoma
Experts on urothelial carcinoma
Susan Domchek, MD, FASCO
Expert on CSCC
Expert on CSCC
Experts on BTC
Experts on BTC
Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,
Expert on AML
Expert on AML
Related Content